Clinical Trial VICCGI1012

Title

Foregut Mircobiome in Development of Esophageal Adenocarcinoma (Clinical Sampling Protocol)

Principal Investigator(s)

Patrick Yachimski

Details

  • Protocol No. VICCGI1012
  • Open Date: 03/05/2010
  • Staging: NA
  • Age Group: Adults
  • Scope: National
  • Objective: Diseases: Healthy controls, RE, BE, EA; We will demonstrate the overall association of the foregut microbiome with the development of RE, BE, and EA (GERD progression). A) If samples of the microbiome can be classified into three or more different types, we will determine whether different stages of GERD progression are significantly associated with exposure to different types of microbiome. If not, we will proceed to primary objective B. B) If samples of the microbiome can be classified into only two types, normal and abnormal, similar to what we had observed in our preliminary study, we will determine whether each of the disease stages in GERD progression is significantly associated with exposure to the abnormal type of microbiome at the disease site. If not, we will proceed to primary objective C. C) To determine whether a later stage disease of GERD progression is significantly associated with a higher degree of exposure to abnormal microbiome than an early stage disease.
  • Disease Sites: Gastrointestinal; Esophageal
  • Therapies: Correlative
  • Drugs: None Specified
  • Participating Institutions: Vanderbilt University
  • Secondary Protocol No: Not Specified

Description

Eligibility

Learn More

You do not have JavaScript enabled. This site works better with JavaScript turned on.